April 11, 2013
First EU JETREA
order triggers €45 million milestone payment from Alcon to ThromboGenics
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today announces that its partner Alcon has launched JETREA
(ocriplasmin) in the UK, its first market in
. The first sale of JETREA
by Alcon triggers a €45 million milestone payment to ThromboGenics. ThromboGenics recently received €45 million from Alcon when JETREA
gained European approval for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
Alcon, a division of Novartis, acquired the rights to commercialize JETREA
the United States
. ThromboGenics retains the right to commercialize the drug in the US. ThromboGenics launched JETREA
in the US in
where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA).
is currently undergoing a single technology appraisal (STA) by the National Institute for Health and Care Excellence (NICE) as part of the process to gain reimbursement when used by the UK National Health Service. The outcome of the STA, in the form of NICE guidance, is expected in the final quarter of 2013.
Dr Patrik De Haes, CEO of ThromboGenics, says:
The launch of JETREA
by Alcon so shortly after gaining European approval is testimony of our joint commitment to ensuring patients in Europe have access to this innovative drug as soon as possible. The additional €45 million payment from Alcon for reaching this milestone means we are well placed to continue investing in the commercialization of JETREA
via our own commercial organization. We expect that Alcon will roll out
into other European markets in the coming months and are working with our partner to ensure that all the support for physicians, payers and patients is fully in place.
contains the active substance ocriplasmin. It is administered through a one-time, single intravitreal injection to treat adults with vitreomacular traction (VMT).
VMT, which in the US is referred to as symptomatic VMA, is an age-related progressive, sight-threatening condition. It is caused by the vitreous humour having an abnormally strong attachment to the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognising faces.